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Abstract
Background: A-kinase Anchoring Protein AKAP5 and AKAP12 both dock to the β2-adrenergic
receptor, the former constitutively, the latter dynamically in response to activation of the receptor
with agonist.
Results:  In the current work we analyze the ability of each AKAP to contribute to two
downstream signaling events, the activation of mitogen-activate protein kinase and the
resensitization/recycling of the internalized, desensitized  β2-adrenergic receptor to the cell
membrane. Although both AKAP share a large number of docking partners in common (e.g., β2-
adrenergic receptor, protein kinases A and C, protein phosphatase-2B, and negatively-charged
membrane phospholipids), AKAP5 and AKAP12 are shown to segregate with respect to activation
of Erk1,2 and to resensitization/recycling of β2-adrenergic receptor. A431 cells were found to
highly express AKAP12, but little of AKAP5. HEK293 cells, in contrast, were found to highly
express AKAP5, but little of AKAP12. Suppression of the expression of AKAP5 in either A431 cells
or HEK293 cells leads to loss of the ability of the β2-adrenergic receptor to activate Erk1,2.
Suppression of the expression of AKAP12 in either cell line leads to loss of the ability of these cells
to resensitize the β2-adrenergic receptor.
Conclusion: Knock-down experiments of endogenous AKAP 5 and AKAP12 in two cell lines used
commonly to study β2-adrenergic receptor signaling clearly discriminate between the activation of
mitogen-activated protein kinase (a downstream read-out solely mediated by AKAP5) and
receptor recycling (a downstream read-out solely mediated by AKAP12).
Background
The identification of a class of proteins harboring a bind-
ing site for the regulatory subunits (i.e., RI/RII) of cyclic
AMP-dependent protein kinase A (PKA, A-kinase) was
seminal in our understanding of the roles of these scaffold
proteins, termed A-Kinase Anchoring Proteins or AKAPs,
in cellular signaling [1]. The ability of AKAPs to dock PKA
was followed by the discovery that AKAPs can act as
molecular "tool boxes" that are multivalent and capable
of docking PKA, protein kinase C (PKC), as well as phos-
phoprotein phosphatases, such as protein phosphatase-
2B [2]. AKAPs have been shown to participate in macro-
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molecular signaling complexes that include protein
kinases (serine/threonine and tyrosine kinases), phos-
phatases, phosphodiesterases (PDE), adaptor molecules,
ion channels, and also at least one member of the super-
family of G protein-coupled receptors (GPCR) [3]. Two
AKAPs that associate with the prototypic GPCR, the β2-
adrenergic receptor, have been the focus of intense
research. Herein, we examine these two members of the
class of GPCR-associated AKAPs, namely AKAP5 (also
known as AKAP79/150) and AKAP12 (also known as
gravin and AKAP250), comparing and contrasting struc-
ture/function, conserved domains and motifs, and details
about their roles in two well known cellular signaling
responses. We elucidate the role of each of these AKAP
"molecular tool boxes" in mediating mitogen-activated
protein kinase activation and in mediating GPCR resensi-
tization and cyclic AMP generation.
Results
AKAP5 and AKAP12 are molecular tool boxes that dock to
GPCR, e.g., β2-adrenergic receptor. In view of their many
common properties, including the docking to GPCR, we
probed if AKAP5 and AKAP12 shared common functions
in downstream signaling. We made use of two cell lines
often employed in studies of one or the other AKAP [4-
10], the human embryonic stem cell (HEK293) and the
human epidermoid carcinoma cell (A431). We sought to
evaluate the relative levels of expression of both AKAP5
and AKAP12 in these two well-known cell lines employed
in studies of cell signaling, particularly signaling via
GPCRs. The most informative identification of and assay
of abundance of AKAPs is the use of the A-kinase overlay
assay (fig. 1). In this assay, equivalent amounts of cellular
protein are subjected to SDS-PAGE, the resolved proteins
transferred to blots, and the presence of AKAPs identified
by overlaying the blots with A-kinase RII α-subunit [11].
For the A431 cells, AKAP12 (250 kDa-Mr) plus a ~170
kDa-Mr proteolytic AKAP12 fragment were dominant spe-
cies in the overlay assay and readily detected also in com-
panion immunoblotting of the same samples using anti-
AKAP12 antibodies. What is equally obvious is that for
HEK293 cells, AKAP5 (79 kDa-Mr) is readily stained by
the overlay assay, an observation confirmed in the immu-
noblotting of the same samples using anti-AKAP5 anti-
bodies (fig. 1). Perhaps even more of interest is not only
that these cells lines express a dominant AKAP, but in the
case of the A431 cells, AKAP12 is dominant, whereas
AKAP5 is expressed to a relatively minor level. For
HEK293 cells, the expression levels of these two AKAPs
clearly were reversed, i.e., AKAP5 is the dominant AKAP
and AKAP12 is expressed at markedly lower relative levels.
Thus we can approach analysis of AKAP function for these
two AKAPs, making use of cell lines that natively are
replete in one and largely deficient of the other AKAP (fig.
1).
One of most interesting signaling outputs for β2-adrener-
gic receptors is the initiation of the mitogen-activated pro-
tein kinase cascade that leads to activation of Erk1,2. We
assayed the activation of Erk1,2 in whole-cell homoge-
nates by use of immunoblotting with activation-specific,
phospho-specific antibodies to Erk1,2 (fig. 2). Treating
wild-type A431 cells with the β2-adrenergic agonist iso-
proterenol (10 μM) for 0–30 min provokes a clear and
marked activation of Erk1 (pErk1 = 44 kDa-Mr) and Erk2
(pErk2 = 42 kDa-Mr), while not changing the relative lev-
els of either Erk1 or Erk2. Within 5 min of challenge with
isoproterenol, levels of activated pERK1,2 increase mark-
edly, a response that peaks at 10 min and thereafter slowly
declines.
Since wild-type A431 cells express both AKAP5 (minor)
and AKAP12 (dominant), we sought to determine in these
cells which of the AKAPs is involved in mediating the sig-
naling from the β2-adrenergic receptor to Erk1,2 activa-
tion. To address this question we made use of siRNA
designed to suppress (i.e., knock-down, KD) the expres-
sion of either hAKAP5 or hAKAP12. As observed in the
immunoblots of whole-cell homogenates stained with
anti-AKAP12 antibodies, siRNA treatment knocked-down
the expression of AKAP12 by more than 95%. The ability
of isoproterenol to stimulate activation of Erk1,2 was
largely unaffected by the nearly total suppression of the
Overlay analysis of A kinase-anchoring proteins in A431 and  HEK cells Figure 1
Overlay analysis of A kinase-anchoring proteins in 
A431 and HEK cells. Cell lysates (50 μg of protein/lane) of 
A431 or HEK cells were subjected to SDS-polyacrylamide gel 
electrophoresis, the resolved proteins transferred to nitro-
cellulose blots, and the blots subjected to renaturation and 
stained with A-kinase RII subunit for 2 h at room tempera-
ture. After washing, the presence of AKAPs was detected 
using an goat anti-RII antibody. The resultant blots also were 
stained with antibodies specific for AKAP12 or AKAP5.Journal of Molecular Signaling 2008, 3:19 http://www.jmolecularsignaling.com/content/3/1/19
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dominant AKAP12 in this cell line. siRNAs designed to
knock-down AKAP5 were equally effective in suppressing
expression of AKAP5, as shown in an overexposure of an
immunoblot of AKAP5 expression in whole-cell homoge-
nates of A431 cells. The ability of isoproterenol treatment
to activate Erk1,2 in A431 cells was abolished when the
expression of AKAP5, but not AKAP12, was knocked
down. The effects of simultaneous knock-down of AKAP5
and AKAP12 displayed the same ability to block Erk1,2
activation as did knock-down of AKAP5 alone.
Activation of the mitogen-activated protein kinase cascade to Erk1,2 in human epidermoid A431 cells in response to isoproter- enol stimulation Figure 2
Activation of the mitogen-activated protein kinase cascade to Erk1,2 in human epidermoid A431 cells in 
response to isoproterenol stimulation. Wild-type 431 or A431 cells treated with siRNAs targeting either AKAP12 or 
AKAP5, or both AKAPs, were stimulated by isoproterenol (10 μM) for different intervals. Cell lysates were subjected to SDS-
polyacrylamide gel electrophoresis, the resolved proteins transferred to nitrocellulose. The blots were stained by antibody 
against activation-specific phospho-Erk1,2, against pan-Erk, or against AKAP12 and AKAP5.Journal of Molecular Signaling 2008, 3:19 http://www.jmolecularsignaling.com/content/3/1/19
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In HEK293 cells, identical experiments were performed.
The main difference being that the HEK cells have just the
opposite relative distribution of AKAP5 (dominant) and
of AKAP12 (minor). HEK293 cells displayed a rapid (≤ 5
min) and robust Erk1,2 activation in response to isoprot-
erenol (fig. 3). siRNA-induced knock-down effectively
suppressed the expression of one or both of the AKAPs in
these cells. Again, as in the A431 cells, the knock-down of
Activation of the mitogen-activated protein kinase cascade to Erk1,2 in human embryonic kidney 293 cells in response to iso- proterenol stimulation Figure 3
Activation of the mitogen-activated protein kinase cascade to Erk1,2 in human embryonic kidney 293 cells in 
response to isoproterenol stimulation. Wild-type HEK293 cells or HEK293 cells treated with siRNAs targeting either 
AKAP12 or AKAP5, or both AKAPs, were stimulated by isoproterenol (10 μM) for different intervals. Cell lysates were sub-
jected to SDS-polyacrylamide gel electrophoresis, the resolved proteins transferred to nitrocellulose. The blots were stained 
by antibody against activation-specific phospho-Erk1,2, against pan-Erk, or against AKAP12 and AKAP5.Journal of Molecular Signaling 2008, 3:19 http://www.jmolecularsignaling.com/content/3/1/19
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AKAP12 in HEK293 cells had no effect on the ability of
isoproterenol to activate Erk1,2. Suppression of AKAP5, in
contrast, again blocks the Erk1,2 activation in response to
isoproterenol, both in cells which express either high
(HEK293 cells) or low (A431 cells) levels of endogenous
AKAP5 (fig. 3). Thus in both A431 and HEK293 cells,
AKAP5, but not AKAP12, mediates activation of the
mitogen-activated protein kinase cascade in response to β-
adrenergic stimulation.
Another function first observed to be mediated by
AKAP12 (gravin) is the resensitization and recycling of the
β2-adrenergic receptor. AKAP12 does not function in
either the agonist-specific desensitization or the internali-
zation of GPCRs [3,12,13]. Rather, once desensitization
and internalization of β2-adrenergic receptors is complete,
AKAP12 plays an essential function in the resensitization
(dephosphorylation) of the receptors and in the recycling
of the receptors from intracellular vesicles, mobilizing
them to the cell membrane [12]. With respect to stimula-
tion of cyclic AMP accumulation (over a 5 min period),
wild-type A431 cells treated with isoproterenol for 30 min
are fully "desensitized" to a second stimulation with the
β-adrenergic agonist (+ Isoproterenol, 30 min, fig. 4). If
the agonist is washed away, the cells nearly fully recover
within the next 30 min (Wash out, W60 min, fig. 4). Thus,
the cells have a robust stimulation of cyclic AMP, display
agonist-induced desensitization, and recovery to the con-
trol response within 30 min of a wash-out of the agonist
(fig. 4).
When A431 cells, replete in AKAP12 but not AKAP5, were
treated with siRNA to knock-down the expression of
AKAP12 (KD AKAP12), the ability of the cells to recover
their cyclic AMP response to isoproterenol following a
washout of agonist was largely blunted (fig. 4). Similar
treatment of the cells with siRNA targeting expression of
AKAP5 (KD AKAP5), in contrast, had no effect on the abil-
ity of the cells to recover their cyclic AMP response (fig. 4).
When cells were simultaneously treated with siRNAs tar-
geting both AKAP5 and AKAP12, the recovery of the cells
from agonist-induced desensitization following a wash-
out was nearly abolished, much like the response of the
cells to siRNA targeting the AKAP12 only (fig. 4). These
data clearly demonstrate that expression of AKAP12, but
not AKAP5, is essential to the ability of cells to recover
from agonist-induced desensitization. AKAP 5 appears to
play no significant role in this AKAP function.
Parallel studies were performed in the HEK293 cells in
which AKAP5 expression is highly abundant and AKAP12
is considerably less (figs. 1, 5). The cyclic AMP response of
the HEK293 cells to initial stimulation, but no pre-incu-
bation with isoproterenol (fig. 5) was similar to that
observed in the A431 cells (fig. 4). Likewise, pretreatment
with the β-adrenergic agonist provoked a marked desensi-
tization to a subsequent challenge with isoproterenol. The
agonist-induced desensitized state of the HEK293 cells
was largely reversed once the cells were washed free of
agonist and allowed to recover for 30 min. The siRNA-
induced knock-down of AKAP12 in HEK293 cells had no
effect on the initial stimulatory cyclic AMP response to
agonist and did not influence the extent to which the cells
were desensitized by prior treatment with agonist for 30
min (fig. 5). Suppression of AKAP12 (KD AKAP12) clearly
abolished the ability of these cells to recover from agonist-
induced desensitization, once the agonist was washed free
(fig. 5). Parallel experiments performed using siRNAs tar-
geting AKAP5 expression (KD AKAP5) had no effect on
the stimulatory response, the ability of the cells to display
agonist-induced desensitization, as well as recovery and
resensitization from agonist-induced desensitization once
the HEK293 cells were washed free of agonist (fig. 5).
Treatment with siRNAs individually targeting both AKAP5
and AKAP12 provoked a loss in the ability of these cells to
recover and to re-sensitize from agonist-induced desensi-
tization much like that observed when on the AKAP12
was knocked-down. Thus, even in the cells which natively
express relative high levels of AKAP5 and low levels of
AKAP12 (fig. 1), AKAP12 appears to be playing the dom-
inant role of catalyzing the recovery of the cells from ago-
nist-induced resensitization. In the absence of AKAP12,
normal recovery and resensitization does not occur fol-
lowing wash-out of the β-adrenergic agonist.
Discussion
The functional roles of AKAPs in general [14] and the
GPCR-associated AKAP specifically [3] are just beginning
to be described in fine detail. AKAP5 and AKAP12 are
early members of the AKAP family, a family that continues
to expand its membership. AKAP5 and AKAP12 share an
impressive list of properties in common: dock PKA RII
subunit (by definition), protein phosphatase-2B, and pro-
tein kinase C; display three N-terminal, small positively-
charged domains (PCD) that electrostatically bind to the
inner leaflet of the lipid bilayer; and, dock to a prominent
member (and likely others) of the superfamily of GPCR,
the β2-adrenergic receptor [15]. In the current study we
focus on two centrally important functions in which
AKAPs have exerted functions in organizing downstream
signaling: activation of the mitogen-activated protein
kinase cascade terminating in Erk1,2 activation; and,
catalysis of the resensitization and recycling of the GPCRs
that have been subjected to agonist-induced desensitiza-
tion. Since AKAP5 and AKAP12 have been implied to have
similar roles and each has shown the capacity to interact
with the β-adrenergic receptor we compared these two
AKAPs for there ability to catalyze one or the other, or
both, of these functional read-outs.Journal of Molecular Signaling 2008, 3:19 http://www.jmolecularsignaling.com/content/3/1/19
Page 6 of 11
(page number not for citation purposes)
The studies were performed in two cell types that are com-
monly used to study cell signaling, especially GPCR-medi-
ated activation of cyclic AMP accumulation and of the
MAP kinase cascade. Of interest were the results of the ini-
tial characterization of these two cell lines with respect to
the expression of the two AKAPs targeted in these studies.
It would be challenging to compare the expression of
these two different scaffolds if they did not share a com-
mon docking partner that appears to bind in a molar 1:1
manner and stoichiometrically. Using A-kinase RII subu-
Desensitization and Resensitization of β2AR in wild-type A431 cells and cells treated to knock-down AKAP12 or AKAP5 Figure 4
Desensitization and Resensitization of β2AR in wild-type A431 cells and cells treated to knock-down AKAP12 
or AKAP5. A, cyclic AMP accumulation of β2AR-mediated cyclic AMP accumulation in A431 cells that were desensitized by 30 
min treatment with Iso and then washed free of agonist for 60 min (W60) to permit resensitization was examined. Agonist-
stimulated (Iso,10 μM) cyclic AMP accumulation was measured in untreated cells, in cells following a 30-min prior stimulation 
with Iso, and in cells treated with Iso for 30 min, washed free of agonist, incubated for 60 min and then assayed (W60). A431 
cells were pretreated either with a control, scrambled sequence siRNA (Control) or with siRNA targeting AKAP12/AKAP5 to 
knock down (KD) the expression of endogenous AKAP12 or AKAP5. Cells were challenged with a β2-adrenergic agonist (Iso, 
10 μM) for 30 min to provoke agonist-induced desensitization and internalization of β2AR. The recovery from agonist-induced 
desensitization, termed resensitization, was measured in cells after a 30-min challenge with Iso, and in Iso-treated cells that 
were washed free of agonist for 60 min (W60). Isoproterenol-stimulated cyclic AMP accumulation was measured in these cells 
and is reported as picomol of cyclic AMP accumulated per 105 cells. The results, displayed as mean ± S.E., are derived from at 
least three separate experiments performed with as many separate cultures of A431 cells. *, p ≤ 0.01 for the difference from 
the amount of cyclic AMP accumulation measured in the control cells at 60 min following a washout of the agonist (W60).Journal of Molecular Signaling 2008, 3:19 http://www.jmolecularsignaling.com/content/3/1/19
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nit to probe blots from similar amount of whole-cell
homogenates of HEK293 and A431 cells, we were able to
demonstrate a remarkable difference between these cell
lines, long favored in cell signaling studies of the cyclic
AMP response [10,16]. HEK293 and A431 cells differ
markedly with respect to expression of AKAP5; by A-
Desensitization and Resensitization of β2AR in wild-type HEK293 cells and cells in which AKAP12 or AKAP5 were knocked- down Figure 5
Desensitization and Resensitization of β2AR in wild-type HEK293 cells and cells in which AKAP12 or AKAP5 
were knocked-down. A, cyclic β2AR-mediated cyclic AMP accumulation in HEK cells that were desensitized by 30 min treat-
ment with Iso and then washed free of agonist for 60 min (W60) to permit resensitization was examined. Agonist-stimulated 
(Iso,10 μM) cyclic AMP accumulation was measured in untreated cells, in cells following a 30-min prior stimulation with Iso, and 
in cells treated with Iso for 30 min, washed free of agonist, incubated for 60 min and then assayed (W60). HEK cells were pre-
treated with either a control, scrambled sequence siRNA (Control) or with siRNA to AKAP12 or AKAP5 to knock down (KD) 
the expression of endogenous AKAP12 or AKAP5. Cells were challenged with a β2-adrenergic agonist (Iso,10 μM) for 30 min 
to provoke agonist-induced desensitization and internalization of β2AR. The recovery from agonist-induced desensitization, 
termed resensitization, was measured in cells after a 30-min challenge with Iso, and in Iso-treated cells that were washed free 
of agonist for 60 min (W60). Isoproterenol-stimulated cyclic AMP accumulation was measured in these cells and is reported as 
picomol of cyclic AMP accumulated per 105 cells. The results, displayed as mean ± S.E., are derived from at least three separate 
experiments performed with as many separate cultures of A431 cells. *, p ≤ 0.01 for the difference from the amount of cyclic 
AMP accumulation measured in the control cells at 60 min following a washout of the agonist (W60).Journal of Molecular Signaling 2008, 3:19 http://www.jmolecularsignaling.com/content/3/1/19
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kinase RII staining in the former, AKAP5 (79 kDA-Mr) is
shown to be the dominant AKAP family member
expressed, whereas in the latter AKAP5 is shown to be
only a minor AKAP. With respect to AKAP12, its abun-
dance (including the 250 kDa-Mr parent as well as the
~170 kDa-Mr proteolytic fragment) is high in A431 cells
and low in HEK293 cells. Thus in choosing to analyze the
function of AKAP5 and AKAP12 in these two cell lines, we
are probing conditions in which natively one AKAP form
is dominant, while the other is a relatively minor species.
In both cases, siRNA-induced knock-down of targeted
AKAP was effective, regardless of whether it was the major
or minor AKAP in the cell line under study.
The outcome was remarkable in one major sense, the
functional properties of AKAP 5 and AKAP12 with regard
to the two prominent read-outs was very clear. AKAP5
was essential for expression of the ability of the GPCR β-
adrenergic receptor to mediate the activation of the MAP
kinase cascade to the level of Erk1,2, whereas AKAP12
was truly dispensable. This result was confirmed by stud-
ies using both cell lines. AKAP12, in contrast, was found
to be essential for the ability of the cells to recover from
agonist-induced desensitization (a hallmark for virtually
all members of the GPCR superfamily of receptors) and
yield re-sensitized, recycled receptors to the cell mem-
brane. Again, this result was confirmed by studies using
both cell lines (fig. 6). Thus, in spite of the many prop-
erties that AKAP5 and AKAP12 share, with respect to
mediating the activation of the mitogen-activated pro-
tein kinase cascade to the level of Erk1,2 as well as with
respect to mediating the recovery, resensitization and
recycling of agonist-induced desensitized receptors these
two AKAPs display no  redundancy in function. Both
AKAPs display docking of many partners in common
(e.g., A-kinase RII subunit, protein kinase C, and the β-
adrenergic receptor), then it must be the temporal
sequence of docking, the dynamics of docking, or the
docking of some partners not shared in common respon-
sible for this difference in function. The most obvious
insight to the basis for this lack of redundancy in these
two downstream read-outs is the report that AKAP12
docks to the GPCR in a dynamic manner [2,3,13],
whereas AKAP5 has been reported to dock constitutively
[4]. The receptor-binding domain (RBD) of AKAP12 has
been characterized structurally and is known to possess
multiple A-kinase sites of phosphorylation [13]. AKAP5
has a sequence with some analogy to the AKAP12 RBD,
which also includes sites (potential) for A-kinase phos-
phorylation [15], but this putative AKAP5 RBD needs
careful and thorough characterization before we can rule
the differences in the RBD to be important, or not, in the
unique downstream signaling mediated by AKAP12 ver-
sus AKAP5.
The other avenue worthy of careful investigation is the
trafficking of the AKAPs and the β-adrenergic receptors
during receptor activation, desensitization, internaliza-
tion, recovery, resensitization, and recycling to the cell
membrane. Differences in the trafficking patterns of the
AKAP may reveal how these two central functions of
AKAP5 and AKAP12 can be compartmentalized in cells
replete with both as well as deficient in one. Although the
domain of the β2-adrenergic receptor that is the site of
docking of AKAP12 (through the RBD) has been deter-
mined, one cannot assume that both AKAP12 and AKAP5
share the same docking site on the GPCR. If the dock site
of the GPCR for these two AKAPs was common, one
might expect that there would be some differences per-
haps in the properties of the responses between cells in
which one AKAP is the dominant form, while the other
AKAP is a minor form. If the binding site on the GPCR
were common and capable of interacting with either
AKAP, overexpression of one AKAP (even natively) might
be expected to act as a dominant negative of the function
of the other AKAP. Knock-down studies of AKAP5/12
function in which we suppressed the expression of a single
AKAP were compared to parallel studies in which we
simultaneously suppressed the expression of both scaf-
folds. The results of this comparison do not support the
notion that AKAP5 and AKAP12 share the same site of
interaction on the GPCR. Clearly the roles of each AKAP
as well as their possible interaction must be considered
and probed to further delineate the functional roles of
these interesting scaffold molecules.
Conclusion
Human epidermoid carcinoma A431 cells and human
embryonic kidney 293 cells express a different ratio of two
AKAPs that are known to dock to G protein-coupled
receptors. A431 cells natively express a variety of AKAP
family members, AKAP12 being dominant in expression
and AKAP5 being minor. HEK293 cells, in contrast,
natively express relatively high amounts of AKAP5 and
comparatively little AKAP5. We examined two well
known read-outs (i.e., activation of Erk1,2 and the resen-
sitization/recycling of G protein-coupled receptors) that
are downstream to and regulated by the β2-adrenergic
receptor, a prototypic G protein-coupled receptor. The
beta-adrenergic agonist isoproterenol stimulates these
two downstream responses in both cell types. Knock-
down of AKAP5 abolishes the Erk1,2 activation; knock-
down of AKAP12 blocks the ability of the cells to resensi-
tize and recycle the internalized/desensitized β2-adrener-
gic receptor back to the cell membrane. This study reveals
an unexpected discrimination by AKAP5/AKAP12 among
downstream signaling pathways from G protein-coupled
receptors. Both AKAP scaffolds share many docking part-
ners (e.g., protein kinases A and C, phosphoprotein phos-Journal of Molecular Signaling 2008, 3:19 http://www.jmolecularsignaling.com/content/3/1/19
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phatase-2B,  β2-adrenergic receptor, and adaptor
molecules) as well as interact dynamically with the cell
membrane, yet cleanly discriminate between Erk 1,2 acti-
vation and receptor resensitization/recycling.
Methods
Cell culture
Human epidermoid carcinoma cells (A431) and human
embryonic kidney cells (HEK293) were maintained in
Dulbecco's modified Eagle's medium supplemented with
10% fetal bovine serum (HyClone, Logan, UT), penicillin
(60 μg/ml), and streptomycin (100 μg/ml) and grown in
a humidified atmosphere of 5% CO2 and 95% air at
37°C.
siRNA-induced knock-down of AKAP5 and AKAP12
siRNAs targeting human AKAP5 (aagagaucagcagaag-
guagu) corresponding to nucleotides 48–68 or a "scram-
bled" siRNA control (aaggcaacaaaggcuaaguca) as well as
those targeting human AKAP12 (cgaggcggcgccagacaccac)
Schematic of GPCR-associated AKAP79 and AKAP250: regulation of downstream signaling by beta2-adrenergic receptors Figure 6
Schematic of GPCR-associated AKAP79 and AKAP250: regulation of downstream signaling by beta2-adrener-
gic receptors. The AKAPs provide multivalent docking sites for PKA, PKC, and PP2B as well as other protein kinases, phos-
phoprotein phosphatases, and adaptor molecules (not shown). Binding of the beta-adrenergic agonist leads to activation of the 
receptor (β2AR*, #1) and activation of Gs > adenylylcyclase activation > cyclic AMP accumulation > PKA activation (#2). The 
association of AKAP250 with the receptor is markedly enhanced by PKA phosphorylation of the receptor and scaffold, 
whereas AKAP79 association with the receptor is constitutive. AKAP79 mediates downstream signal switching from Gs to Gi-
mediated activation of the mitogen-activated protein kinase cascade leading to Erk1,2 (#3). AKAP250 mediates the resensitiza-
tion and recycling of the desensitized and internalized receptor (#4). Through docking of critical enzymes, the AKAP provide 
high spatial resolution and localization of downstream signaling. See the text for more details.
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corresponding to nucleotides 161–181 or a "scrambled"
siRNA control (ggagcgcggcgaccaacccca) were synthesized
by Invitrogen (Calsbad, CA). siRNAs were transfected at a
concentration of 50–100 nM into A431 or HEK-293 by
the Lipofectamine 2000™ transfection reagent (Invitro-
gen). After 2 days, cell extracts were probed to determine
the expression of each AKAP, so as to assess both the
extent of the siRNA-induced suppression and specificity.
Analysis of expression of AKAPs
Following siRNA-induced suppression of AKAP expres-
sion, the amount of residual AKAP was probed by immu-
noblotting. Cells were harvested and lysed in a lysis buffer
(1% Triton X-100, 0.5% Nonidet-40, 10 mM dithiothrei-
tol, 5 μg/ml aprotinin, 5 μg/ml leupeptin, 100 μg/ml baci-
tracin, 100 μg/ml benzamidine, 2 mM sodium
orthovanadate, 150 mM NaCl, 5 mM EDTA, 50 mM NaF,
40 mM sodium pyrophosphate, 50 mM KH2PO4, 10 mM
sodium molybdate, and 20 mM Tris-HCl, pH 7.4) at 4°C
for 20 min. The samples were subjected to SDS-PAGE and
the resolved proteins transferred electrophoretically to
nitrocellulose blots. The blots were stained with primary
antibodies (anti-AKAP79 from Upstate; anti-gravin kindly
provided by Dr. John Scott) and detected with a secondary
antibody. Immune complexes were made visible with ECL
staining [17].
Immunoblotting and quantification analysis of proteins
Proteins (60–100 μg samples) were analyzed by SDS-
polyacrylamide gel electrophoresis and transferred elec-
trophoretically to an Immobilon membrane (Millipore,
Bedford, MA). The blots were stained with the primary
antibodies indicated. Immunoreactive bands were
detected using a horseradish peroxidase-conjugated, sec-
ondary antibody in tandem with ECL chemilumines-
cence. Exposed films were scanned by calibrated Umax
1000 absorbance scanner equipped with SilverFastAi soft-
ware (LaserSoft Imaging Inc. Longboat Key, FL). The
bands were quantified by use of Aida® software (Raytest,
Germany) [18].
Mitogen-activated protein kinase assay
To assay Erk1,2, whole-cell homogenates were subjected
to SDS-PAGE, as described above, and the blots then were
probed with specific antibodies that cross-react with phos-
phorylated-activated forms of Erk1,2 (Thr202/Tyr204) or
pan-ERK, to establish Erk protein levels. Use of secondary
antibodies, staining, detection, and the quantification
were as described above.
RII overlay assay
Fifty micrograms of cell lysate or membrane protein was
separated by electrophoresis on an SDS-polyacrylamide
gel and transferred electrophoretically to nitrocellulose
blots. The blots first were blocked with a Tris-buffered
saline solution containing 10% heat-inactivated horse
serum and then incubated with RII subunit for 2 h at
room temperature. After washing, the presence of AKAPs
was detected using an goat anti-RII α antibody, as
described in immunoblotting analysis [3].
Protocols for desensitization and resensitization of β2AR
Two days prior to the analysis of agonist-induced desensi-
tization, the A431 cells were seeded in 96-well microtiter
plates at a density of 25,000–50,000 cells/well. Routinely
cells were serum-starved overnight, prior to analysis. For
the current studies the cells were sampled for their capac-
ity to accumulate cyclic AMP over a 5-min interval in
response to 10 μM isoproterenol in one of three standard
protocols [19]: cells with no extended pre-incubation
with isoproterenol (+ Isoproterenol, "0" time); cells with
30 min of prior incubation with isoproterenol, briefly
washed and then stimulated with the standard 5 min
period of cyclic AMP accumulation (+ Isoproterenol, "30"
time); and, cells pre-treated with isoproterenol for 30
min, washed-free of agonist, and allowed to resensitize for
an additional 30 min (+ Isoproterenol > wash out = W60).
The first protocol is the "control" for β-adrenergic stimu-
lated accumulation of cyclic AMP, the second protocol is
assay for β-adrenergic stimulated accumulation of cyclic
AMP in the agonist-induced "desensitized" state, the third
protocol is the assay for β-adrenergic stimulated accumu-
lation of cyclic AMP in the recovered, "resensitized" state.
Prior challenge with a β-adrenergic agonist severely blunts
cyclic AMP accumulation in response to a second chal-
lenge and this loss in the cyclic AMP response is accompa-
nied by a decline in the number of cell-surface receptors,
as the desensitized receptors are sequestered and internal-
ized. Thirty minutes following wash-out of the agonist,
these desensitized receptors are fully resensitized and are
recycled to the cell membrane. Likewise the cells subjected
to wash-out and a 30-min period in absence of agonist
display a fully-recovered cyclic AMP response to isoproter-
enol. Details of the desensitization/resensitization proto-
cols are described elsewhere [19].
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